$23.10
1.07% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US79957L1008
Symbol
SMTI

Sanara MedTech Inc Stock price

$23.10
+2.90 14.36% 1M
-6.84 22.85% 6M
-0.25 1.07% YTD
-10.00 30.21% 1Y
-22.40 49.23% 3Y
-22.57 49.42% 5Y
+16.40 244.78% 10Y
+8.10 54.00% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.25 1.07%

Key metrics

Basic
Market capitalization
$206.4m
Enterprise Value
$236.6m
Net debt
$30.2m
Cash
$14.9m
Shares outstanding
8.9m
Valuation (TTM | estimate)
P/E
negative | 119.2
P/S
2.0 | 2.0
EV/Sales
2.3 | 2.2
EV/FCF
negative
P/B
33.6
Financial Health
Equity Ratio
44.7%
Return on Equity
-24.5%
ROCE
0.9%
ROIC
-
Debt/Equity
7.3
Financials (TTM | estimate)
Revenue
$101.9m | $105.4m
EBITDA
$4.4m | -
EBIT
$455.0k | $4.3m
Net Income
$-37.5m | $1.7m
Free Cash Flow
$-890.0k
Growth (TTM | estimate)
Revenue
30.5% | 21.6%
EBITDA
1,325.0% | -
EBIT
109.5% | 210.9%
Net Income
-348.4% | 117.9%
Free Cash Flow
55.3%
Margin (TTM | estimate)
Gross
92.3%
EBITDA
4.3% | -
EBIT
0.5%
Net
-36.8% | 1.6%
Free Cash Flow
-0.9%
More
EPS
$-4.3
FCF per Share
$-0.1
Short interest
5.3%
Employees
141
Rev per Employee
$610.0k
Show more

Is Sanara MedTech Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Sanara MedTech Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Sanara MedTech Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Sanara MedTech Inc forecast:

Buy
88%
Hold
13%

Financial data from Sanara MedTech Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
102 102
31% 31%
100%
- Direct Costs 7.90 7.90
3% 3%
8%
94 94
34% 34%
92%
- Selling and Administrative Expenses 85 85
22% 22%
83%
- Research and Development Expense 5.81 5.81
47% 47%
6%
4.41 4.41
1,325% 1,325%
4%
- Depreciation and Amortization 3.95 3.95
10% 10%
4%
EBIT (Operating Income) EBIT 0.46 0.46
110% 110%
0%
Net Profit -37 -37
348% 348%
-37%

In millions USD.

Don't miss a Thing! We will send you all news about Sanara MedTech Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sanara MedTech Inc Stock News

Neutral
GlobeNewsWire
24 days ago
Poised for U.S. market launch in Q1 2027 following the achievement of recent milestones and OsStic's granted patent in 2025 FORT WORTH, TX, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce h...
Neutral
Seeking Alpha
about one month ago
SMTI's surgical segment revenue grew 22% year-over-year in Q3 to $26.3 million. Surgical segment adjusted EBITDA was $4.9 million, at a margin of 18.6%. Following a strategic review, management has decided to discontinue the THP segment despite significant investments that were made.
Neutral
GlobeNewsWire
about one month ago
ATLANTA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Sanara MedTech Inc. (“Sanara” or “the Company”) (NASDAQ: SMTI) complied with federal securities laws. On November 11, 2025, Sanara announced that “the Company initiated a strategic realignment of its business, discontinuing operations of [Tissue Health Plus] to improve its operating efficiency and reallocat...
More Sanara MedTech Inc News

Company Profile

Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.

Head office United States
CEO Ron Nixon
Employees 141
Founded 1982
Website sanaramedtech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today